These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 29016344)

  • 1. Defining Persistent Hotspots: Areas That Fail to Decrease Meaningfully in Prevalence after Multiple Years of Mass Drug Administration with Praziquantel for Control of Schistosomiasis.
    Kittur N; Binder S; Campbell CH; King CH; Kinung'hi S; Olsen A; Magnussen P; Colley DG
    Am J Trop Med Hyg; 2017 Dec; 97(6):1810-1817. PubMed ID: 29016344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistent Hotspots in Schistosomiasis Consortium for Operational Research and Evaluation Studies for Gaining and Sustaining Control of Schistosomiasis after Four Years of Mass Drug Administration of Praziquantel.
    Kittur N; King CH; Campbell CH; Kinung'hi S; Mwinzi PNM; Karanja DMS; N'Goran EK; Phillips AE; Gazzinelli-Guimaraes PH; Olsen A; Magnussen P; Secor WE; Montgomery SP; Utzinger J; Walker JW; Binder S; Colley DG
    Am J Trop Med Hyg; 2019 Sep; 101(3):617-627. PubMed ID: 31287046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modeling Approaches to Predicting Persistent Hotspots in SCORE Studies for Gaining Control of Schistosomiasis Mansoni in Kenya and Tanzania.
    Shen Y; Sung MH; King CH; Binder S; Kittur N; Whalen CC; Colley DG
    J Infect Dis; 2020 Feb; 221(5):796-803. PubMed ID: 31621850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contributions of the Schistosomiasis Consortium for Operational Research and Evaluation (SCORE) to Schistosomiasis Control and Elimination: Key Findings and Messages for Future Goals, Thresholds, and Operational Research.
    Colley DG; Fleming FM; Matendechero SH; Knopp S; Rollinson D; Utzinger J; Castleman JD; Kittur N; King CH; Campbell CH; Kabole FM; Kinung'hi S; Ramzy RMR; Binder S
    Am J Trop Med Hyg; 2020 Jul; 103(1_Suppl):125-134. PubMed ID: 32400345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Environmental Predictors of Schistosomiasis Persistent Hotspots following Mass Treatment with Praziquantel.
    Walker JW; Kittur N; Binder S; Castleman JD; Drake JM; Campbell CH; King CH; Colley DG
    Am J Trop Med Hyg; 2020 Feb; 102(2):328-338. PubMed ID: 31889506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovering, Defining, and Summarizing Persistent Hotspots in SCORE Studies.
    Kittur N; Campbell CH; Binder S; Shen Y; Wiegand RE; Mwanga JR; Kinung'hi SM; Musuva RM; Odiere MR; Matendechero SH; Knopp S; Colley DG
    Am J Trop Med Hyg; 2020 Jul; 103(1_Suppl):24-29. PubMed ID: 32400365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can direct smear results that are routinely collected at health centre level be used for monitoring the impact of mass drug administration with praziquantel on schistosomiasis in Burundi? A preliminary assessment.
    Bizimana P; Polman K; Ortu G; Krit M; Nsabiyumva F; Nkeshimana A; Bijabuka U; Nibakire M; Van Geertruyden JP
    Parasit Vectors; 2020 Apr; 13(1):206. PubMed ID: 32317007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Persistent Hotspot of Schistosoma mansoni Infection in a Five-Year Randomized Trial of Praziquantel Preventative Chemotherapy Strategies.
    Wiegand RE; Mwinzi PNM; Montgomery SP; Chan YL; Andiego K; Omedo M; Muchiri G; Ogutu MO; Rawago F; Odiere MR; Karanja DMS; Secor WE
    J Infect Dis; 2017 Dec; 216(11):1425-1433. PubMed ID: 28968877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidemiology and control of human schistosomiasis in Tanzania.
    Mazigo HD; Nuwaha F; Kinung'hi SM; Morona D; Pinot de Moira A; Wilson S; Heukelbach J; Dunne DW
    Parasit Vectors; 2012 Nov; 5():274. PubMed ID: 23192005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can mass drug administration lead to the sustainable control of schistosomiasis?
    Ross AG; Olveda RM; Chy D; Olveda DU; Li Y; Harn DA; Gray DJ; McManus DP; Tallo V; Chau TN; Williams GM
    J Infect Dis; 2015 Jan; 211(2):283-9. PubMed ID: 25070942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of repeated mass drug administration with praziquantel and track and treat of taeniosis cases on the prevalence of taeniosis in Taenia solium endemic rural communities of Tanzania.
    Braae UC; Magnussen P; Ndawi B; Harrison W; Lekule F; Johansen MV
    Acta Trop; 2017 Jan; 165():246-251. PubMed ID: 26597324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Positive impact of preventative chemotherapy during a national helminth control program: Perception and KAP.
    Mutapi F; Tagwireyi P; Lim R; Mangwanda B; Fourier C; Mduluza T
    PLoS Negl Trop Dis; 2020 Aug; 14(8):e0008494. PubMed ID: 32833994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determining treatment needs at different spatial scales using geostatistical model-based risk estimates of schistosomiasis.
    Schur N; Vounatsou P; Utzinger J
    PLoS Negl Trop Dis; 2012; 6(9):e1773. PubMed ID: 23029570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An interdisciplinary approach to determine schistosomiasis prevalence and administer praziquantel to school-age children in Tanzania.
    Jarrell A; Kawsky J; Johnson T; Voss S; Madan R; Weitkamp T; Wigle P
    Am J Health Syst Pharm; 2013 Nov; 70(21):1880-2. PubMed ID: 24128961
    [No Abstract]   [Full Text] [Related]  

  • 15. Lessons Learned in Conducting Mass Drug Administration for Schistosomiasis Control and Measuring Coverage in an Operational Research Setting.
    Binder S; Campbell CH; Castleman JD; Kittur N; Kinung'hi SM; Olsen A; Magnussen P; Karanja DMS; Mwinzi PNM; Montgomery SP; Secor WE; Phillips AE; Dhanani N; Gazzinelli-Guimaraes PH; Clements MN; N'Goran EK; Meite A; Utzinger J; Hamidou AA; Garba A; Fleming FM; Whalen CC; King CH; Colley DG
    Am J Trop Med Hyg; 2020 Jul; 103(1_Suppl):105-113. PubMed ID: 32400352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Something old, something new: is praziquantel enough for schistosomiasis control?
    Secor WE; Montgomery SP
    Future Med Chem; 2015; 7(6):681-4. PubMed ID: 25996059
    [No Abstract]   [Full Text] [Related]  

  • 17. Review of 2022 WHO guidelines on the control and elimination of schistosomiasis.
    Lo NC; Bezerra FSM; Colley DG; Fleming FM; Homeida M; Kabatereine N; Kabole FM; King CH; Mafe MA; Midzi N; Mutapi F; Mwanga JR; Ramzy RMR; Satrija F; Stothard JR; Traoré MS; Webster JP; Utzinger J; Zhou XN; Danso-Appiah A; Eusebi P; Loker ES; Obonyo CO; Quansah R; Liang S; Vaillant M; Murad MH; Hagan P; Garba A
    Lancet Infect Dis; 2022 Nov; 22(11):e327-e335. PubMed ID: 35594896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High level of Schistosoma mansoni infection in pre-school children in Sierra Leone highlights the need in targeting this age group for praziquantel treatment.
    Hodges MH; Paye J; Koroma MM; Nyorkor ED; Fofonah I; Zhang Y
    Acta Trop; 2012 Nov; 124(2):120-5. PubMed ID: 22820025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Praziquantel coverage in schools and communities targeted for the elimination of urogenital schistosomiasis in Zanzibar: a cross-sectional survey.
    Knopp S; Person B; Ame SM; Ali SM; Muhsin J; Juma S; Khamis IS; Rabone M; Blair L; Fenwick A; Mohammed KA; Rollinson D
    Parasit Vectors; 2016 Jan; 9():5. PubMed ID: 26727915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sociocultural aspects of mass delivery of praziquantel in schistosomiasis control: the Abeokuta experience.
    Adeneye AK; Akinwale OP; Idowu ET; Adewale B; Manafa OU; Sulyman MA; Omotola BD; Akande DO; Mafe MA; Appelt B
    Res Social Adm Pharm; 2007 Jun; 3(2):183-98. PubMed ID: 17561219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.